Verenhennyslääkkeiden

Verenhennyslääkkeiden (Finnish for "anticoagulant drugs") are medications designed to prevent or treat the formation of blood clots. These drugs work by interfering with the body’s clotting mechanisms, thereby reducing the risk of conditions such as deep vein thrombosis, pulmonary embolism, and stroke in patients with atrial fibrillation.

There are two main classes of anticoagulants:

1. **Vitamin K antagonists** (e.g., warfarin): These require regular monitoring of blood clotting time (INR) and can be affected by dietary intake of vitamin K (found in green leafy vegetables).

2. **Direct oral anticoagulants (DOACs)** (e.g., dabigatran, rivaroxaban): These have fewer dietary restrictions and do not require routine blood tests, though they may interact with other medications.

Common uses include prophylaxis after surgery, treatment of existing clots, and long-term management of atrial fibrillation. Patients must be aware of potential bleeding risks and follow prescribed dosing regimens carefully. Proper use of anticoagulants is crucial for preventing life-threatening complications related to blood clotting disorders.